HANSIZHUANG ® (serplulimab) was the first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC – ...

HANSIZHUANG (serplulimab) is the world's first anti-PD-1 mAb for first-line treatment of ES-  SCLC   - HANSIZHUANG (serplulimab) is expected to become the first and only anti-PD-1 ...

The European Medicines Agency approved Afqlir and Opuviz to treat age-related macular degeneration while reiterating its ...

Committee for Human Medicinal Products (CHMP) recommended approval of five novel medicines at its September meeting ...

OPUVIZ, a biosimilar referencing Eylea1 (aflibercept), is Samsung Bioepis and Biogen's second ophthalmology biosimilar to be recommended for marketing authorization by the European Medicines Agency IN ...

OPUVIZ™, a biosimilar referencing Eylea1 (aflibercept), is Samsung Bioepis and Biogen’s second ophthalmology biosimilar to be recommended for marketing authorization by the European Medicines Agency ...

Alteogen announced that it has applied for marketing authorization in Korea for ALT-L9, an aflibercept biosimilar ...

Switching children with juvenile idiopathic arthritis (JIA) from anti-tumor necrosis factor (TNF) originators to biosimilars ...

The European Medicines Agency advised its member state regulatory partners to closely track how they use LLMs in making regulatory decisions – a clear signal that some regulatory decisions may be ...

Without widespread access to biosimilars, thousands of cancer patients are losing their battle. Life-saving treatment is not ...

Of the patients in the study, 16.41% received originator products, 87.22% received biosimilars, 3.6% received both a biosimilar and an originator, and 6.2% were treated with both adalimumab and ...

Seabelife SAS’s drug candidate SBL-01 has been awarded European orphan drug designation by the EMA for the treatment of acute liver failure.